Investigation and management of the monoclonal gammopathy of undetermined significance
Authors:
- Simon SternSSSimon Stern
- The Haemato‐Oncology Task Force Of The British Society For Haematology And The Uk Myeloma ForumTFThe Haemato‐Oncology Task Force Of The British Society For Haematology And The Uk Myeloma Forum
- 18 May 2023
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 202 (4) , 734-744
Abstract
Summary: This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.Keywords
Funding Information
- British Society for Haematology (Funding for literature search only)
This publication has 32 references indexed in Scilit:
- Monoclonal gammopathy of undetermined significance: a new proposal of workupEuropean Journal of Haematology, 2013
- Proton NMR-Based Metabolite Analyses of Archived Serial Paired Serum and Urine Samples from Myeloma Patients at Different Stages of Disease Activity Identifies Acetylcarnitine as a Novel Marker of Active DiseasePLOS ONE, 2013
- Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patientsBritish Journal of Haematology, 2012
- Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUSLeukemia, 2012
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementLeukemia, 2010
- Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein SizeMayo Clinic Proceedings, 2007
- Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined SignificanceJournal of Clinical Oncology, 2005
- Fracture Risk in Monoclonal Gammopathy of Undetermined SignificanceJournal of Bone and Mineral Research, 2004
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2002
- Finding MeaningNursing Research, 1988